Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/23065
Title: EPO treatment does not alter acute serum profiles of GFAP and S100B after TBI: A brief report on the Australian EPO-TBI clinical trial.
Authors: Hellewell, Sarah C;Conquest, Alison;Little, Lorraine;Vallance, Shirley;Board, Jasmin;Bellomo, Rinaldo;Cooper, David J;Morganti-Kossmann, Maria Cristina
Affiliation: Department of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia
University of Sydney, Sydney, Australia
Department of Surgery, Alfred Hospital, Melbourne, Australia
Department of Intensive Care, Alfred Hospital, Melbourne, Australia
Australian New Zealand Intensive Care Research Centre, Melbourne, Australia
Department of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
Department of Intensive Care, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 21-Apr-2020
EDate: 2020-04-21
Citation: Journal of Clinical Neuroscience 2020; online first: 21 April
Abstract: To determine the diagnostic and prognostic value of glial fibrillary acidic protein (GFAP) and S100B after traumatic brain injury (TBI) in an Erythropoietin (EPO) clinical trial and examine whether EPO therapy reduces biomarker concentrations. Forty-four patients with moderate-to-severe TBI were enrolled to a sub-study of the EPO-TBI trial. Patients were randomized to either Epoetin alfa 40,000 IU or 1 ml sodium chloride 0.9 as subcutaneous injection within 24 h of TBI. GFAP and S100B were measured in serum by ELISA from D0 (within 24 h of injury, prior to EPO/vehicle administration) to D5. Biomarker concentrations were compared between injury severities, diffuse vs. focal TBI, 6-month outcome scores (GOS-E) and EPO or placebo treatments. At D0 GFAP was significantly higher than S100B (951 pg/mL vs. 476 pg/mL, p = 0.018). ROC analysis of S100B at 1D post-injury distinguished favorable vs. unfavorable outcomes (area under the curve = 0.73; p = 0.01). EPO did not reduce concentration of either biomarker. Elevated serum concentrations of GFAP and S100B after TBI reflect a robust, acute glial response to injury. Consistent with lack of improved outcome in TBI patients treated with EPO and prior findings on neuronal and axonal markers, glial biomarker concentrations and acute profiles were not affected by EPO.
URI: http://ahro.austin.org.au/austinjspui/handle/1/23065
DOI: 10.1016/j.jocn.2020.04.081
ORCID: 0000-0002-1650-8939
PubMed URL: 32331937
Type: Journal Article
Subjects: Biomarker
Erythropoietin
GFAP
S100B
TBI biomarker
Traumatic brain injury
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.